|
|
|
|
Company Name
|
Kringle Pharma, Inc. | |
|
Established
|
December 21, 2001 | |
|
Capital
|
1,474.74 million yen (as of December 2007) | |
|
Audit Corporation
|
KPMG AZSA&Co. | |
|
Main Banks
|
Sumitomo Mitsui Banking Corporation, Mizuho Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd., Resona Bank, Limited, The Shoko Chukin Bank |
|
|
Major Stockholders
|
Nissay Capital Co., Ltd.,
Nippon Life Insurance Company, Nikko antfactory K.K., Nippon Venture Capital Co., Ltd., SBI Investment Co., Ltd., Bio-Sight Capital Co., Ltd., NIF SMBC Ventures Co., Ltd., Nippon Zenyaku Kogyo, Co., Ltd., CSK Venture Capital Co., Ltd., New Business Investment Co., Ltd. |
|
|
Number of Employees
|
20 (as of April 2008) | |
|
Management Concept
|
The most important theme for us in managing our company is to alleviate the patients suffering of cancer patients worldwide by offering a new method of treatment derived from the innovative research and development of HGF and NK4. | |
|
Main Project
|
Research & development of NK4 (pharmaceuticals for cancer therapy) | |
| Research & development of HGF (pharmaceuticals for regenerative medicine) | ||
|
Access |
|
